BioCentury | Nov 8, 2016
Clinical News

SynGEM: Ph I started

...Phase I trial to evaluate 2 intranasal doses of SynGEM in 48 healthy adult volunteers. Mucosis B.V....
...immunogenicity Status: Phase I started Milestone: Interim Phase I data (1H17); start Phase II (mid-2017) Alicia Parker SynGEM Mucosis B.V....
BioCentury | Nov 13, 2014
Cover Story

Boosting adjuvants

...Eurocine Vaccines AB (AktieTorget:EUCI) Phase I/II Bacterium-like particles (BLPs) Self-adjuvanting vehicles FluGEM, an influenza vaccine Mucosis B.V....
BioCentury | Jun 2, 2014
Financial News

Mucosis financial update

...$6.8 million) line of credit from the Dutch Ministry of Economic Affairs' Netherlands Enterprise Agency. Mucosis...
...agency's credit lines "generally mature when a project is successful," such as a commercial launch. Mucosis'...
...respiratory syncytial virus (RSV) vaccine is comprised of BLP-based Mimopath technology carrying trimeric fusion proteins. Mucosis B.V....
BioCentury | Apr 21, 2014
Company News

Changchun BCHT, Mucosis deal

...Changchun received exclusive, Chinese rights and non-exclusive rights in other undisclosed Asian countries to Mucosis' SynGEM...
...make an equity investment in Mucosis, which is also eligible for milestone payments, plus royalties. Mucosis...
...could not be reached. The Mimopath technology is based on the Lactococcus lactis bacteria, which Mucosis...
BioCentury | Apr 21, 2014
Financial News

Mucosis completes venture financing

Mucosis B.V. , Groningen, the Netherlands Business: Infectious Date completed: 4/15/14 Type: Venture financing Raised: €5 million ($6.9 million) Investors: Changchun BCHT Biotechnology; BioGeneration Ventures; MedSciences Capital; NV NOM; Utrecht University Holding WIR Staff...
BioCentury | Oct 15, 2012
Company News

Mucosis, J&J deal

...bacteria, which Mucosis formulates into non-living bacterium-like particles (BLPs) that can be loaded with antigens. Mucosis...
...declined to disclose financial details. J&J acquired Crucell last year (see BioCentury, March 14, 2011). Mucosis B.V....
BioCentury | Oct 1, 2012
Company News

ExpreS2ion, Mucosis, University of Copenhagen infectious news

...ExpreS2 recombinant protein expression platform, which is based on engineered Drosophila Schneider-2 (S2) cells, and Mucosis...
...technologies to a malaria antigen developed by the university. ExpreS2ion Biotechnology ApS , Horsholm, Denmark Mucosis B.V....
BioCentury | Sep 24, 2012
Company News

Mucosis management update

Mucosis B.V. , Groningen, the Netherlands Business: Infectious Transitioned: Thomas Johnston to CEO from CBO; he succeeds Govert Schouten, who departed WIR Staff...
BioCentury | Sep 18, 2012
Company News

Mucosis names Johnston CEO

...Johnston as CEO. He succeeds Govert Schouten, who is departing. Johnston, who was CBO at Mucosis...
...CBO position would remain open and that he would assume both roles in the interim. Mucosis...
...based on its Mimopath technology. The technology is based on the Lactococcus lactis bacteria, which Mucosis...
BioCentury | May 21, 2012
Clinical News

Mucosis preclinical data

...In mice, Mucosis' FluGEM vaccine provided full protection against homologous and heterologous influenza infection, with a...
...and trivalent split influenza antigen. FluGEM is in Phase I testing to prevent influenza infection. Mucosis B.V....
Items per page:
1 - 10 of 18
BioCentury | Nov 8, 2016
Clinical News

SynGEM: Ph I started

...Phase I trial to evaluate 2 intranasal doses of SynGEM in 48 healthy adult volunteers. Mucosis B.V....
...immunogenicity Status: Phase I started Milestone: Interim Phase I data (1H17); start Phase II (mid-2017) Alicia Parker SynGEM Mucosis B.V....
BioCentury | Nov 13, 2014
Cover Story

Boosting adjuvants

...Eurocine Vaccines AB (AktieTorget:EUCI) Phase I/II Bacterium-like particles (BLPs) Self-adjuvanting vehicles FluGEM, an influenza vaccine Mucosis B.V....
BioCentury | Jun 2, 2014
Financial News

Mucosis financial update

...$6.8 million) line of credit from the Dutch Ministry of Economic Affairs' Netherlands Enterprise Agency. Mucosis...
...agency's credit lines "generally mature when a project is successful," such as a commercial launch. Mucosis'...
...respiratory syncytial virus (RSV) vaccine is comprised of BLP-based Mimopath technology carrying trimeric fusion proteins. Mucosis B.V....
BioCentury | Apr 21, 2014
Company News

Changchun BCHT, Mucosis deal

...Changchun received exclusive, Chinese rights and non-exclusive rights in other undisclosed Asian countries to Mucosis' SynGEM...
...make an equity investment in Mucosis, which is also eligible for milestone payments, plus royalties. Mucosis...
...could not be reached. The Mimopath technology is based on the Lactococcus lactis bacteria, which Mucosis...
BioCentury | Apr 21, 2014
Financial News

Mucosis completes venture financing

Mucosis B.V. , Groningen, the Netherlands Business: Infectious Date completed: 4/15/14 Type: Venture financing Raised: €5 million ($6.9 million) Investors: Changchun BCHT Biotechnology; BioGeneration Ventures; MedSciences Capital; NV NOM; Utrecht University Holding WIR Staff...
BioCentury | Oct 15, 2012
Company News

Mucosis, J&J deal

...bacteria, which Mucosis formulates into non-living bacterium-like particles (BLPs) that can be loaded with antigens. Mucosis...
...declined to disclose financial details. J&J acquired Crucell last year (see BioCentury, March 14, 2011). Mucosis B.V....
BioCentury | Oct 1, 2012
Company News

ExpreS2ion, Mucosis, University of Copenhagen infectious news

...ExpreS2 recombinant protein expression platform, which is based on engineered Drosophila Schneider-2 (S2) cells, and Mucosis...
...technologies to a malaria antigen developed by the university. ExpreS2ion Biotechnology ApS , Horsholm, Denmark Mucosis B.V....
BioCentury | Sep 24, 2012
Company News

Mucosis management update

Mucosis B.V. , Groningen, the Netherlands Business: Infectious Transitioned: Thomas Johnston to CEO from CBO; he succeeds Govert Schouten, who departed WIR Staff...
BioCentury | Sep 18, 2012
Company News

Mucosis names Johnston CEO

...Johnston as CEO. He succeeds Govert Schouten, who is departing. Johnston, who was CBO at Mucosis...
...CBO position would remain open and that he would assume both roles in the interim. Mucosis...
...based on its Mimopath technology. The technology is based on the Lactococcus lactis bacteria, which Mucosis...
BioCentury | May 21, 2012
Clinical News

Mucosis preclinical data

...In mice, Mucosis' FluGEM vaccine provided full protection against homologous and heterologous influenza infection, with a...
...and trivalent split influenza antigen. FluGEM is in Phase I testing to prevent influenza infection. Mucosis B.V....
Items per page:
1 - 10 of 18